Mesoblast Ltd
ASX Weekly Wrap: Narrow Leadership, Sticky Core Inflation & Weak Aussie
ASX 200 near 8,764 as Judo Capital dives 39% on funding-cost fears; week capped by hawkish Fed, sticky core inflation and volatile leadership.
Mesoblast’s Ryoncil becomes first cell therapy approved in the US for acute graft-versus-host disease
Regenerative medicine company Mesoblast (ASX: MSB) has been granted US Food and Drug Administration (FDA) approval for its Ryoncil therapy to treat children with steroid-refractory acute graft-versus-host disease (SR-aGvHD). The off-the-shelf drug derived from bone marrow has become the first mesenchymal stromal cell therapy on the US market to treat the condition, which can occur […]
Mesoblast receives coveted FDA designation for Revascor heart treatment
Cellular medicines developer Mesoblast (ASX: MSB) is celebrating the granting of new US Food and Drug Administration (FDA) approval for its Revascor heart disease treatment. The FDA has granted its highly-sought rare pediatric disease (RPD) designation for Revascor following submission of results from a randomised, controlled trial in children with hypoplastic left heart syndrome (HLHS). […]
TPG Global bids for InvoCare, Xero culls workforce and Myer posts record half sales
Private equity firm TPG Global has taken advantage of beleaguered funeral services company InvoCare’s (ASX: IVC) lacklustre FY2022 results, with a non-binding cash takeover offer valuing it at $12.64 per share. Under the non-binding indicative offer, which was made on Tuesday, TPG is proposing to give InvoCare shareholders $12.65 cash for each share held. This […]